Generic drug makers would get more ingredient details from the FDA.
Generic drug makers would get more ingredient details from the FDA when trying to create new versions of existing medicines. This bill would require the FDA to tell companies exactly why their generic drug isn't a perfect match to a brand-name drug. It would also generally require the FDA to stick to its decisions. This aims to make it easier for companies to develop and get approval for generic drugs.
Today, the FDA is not explicitly required to tell generic drug applicants the exact details of inactive ingredient differences. After this bill, the FDA would be required to disclose specific ingredient deviations and their amounts to generic drug applicants upon request, and generally would not be able to change its determination of whether a generic drug is the same as a brand-name drug.
S 1302 · 119th Congress · AI Summary by gemini-2.5-flash · 9/10
Sign in to see your representatives' phone numbers
20 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.